文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

职业治疗主导的自我管理支持方案对初级保健中多种疾病的成本效益。

Cost-effectiveness of an occupational therapy-led self-management support programme for multimorbidity in primary care.

机构信息

Health Economics and Policy Analysis Centre (HEPAC), Institute for Lifecourse & Society (ILAS), CURAM, SFI Research Centre for Medical Devices, NUI Galway, University Road, Galway H91 TK33, Ireland.

Health Economics and Policy Analysis Centre (HEPAC), CURAM, SFI Research Centre for Medical Devices, NUI Galway, University Road, Galway H91 TK33, Ireland.

出版信息

Fam Pract. 2022 Sep 24;39(5):826-833. doi: 10.1093/fampra/cmac006.


DOI:10.1093/fampra/cmac006
PMID:35137039
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9508868/
Abstract

BACKGROUND: Multimorbidity is a major public health concern. Complex interventions, incorporating individualized care plans, may be appropriate for patients with multimorbidity given their individualized and variable needs. There is a dearth of evidence on the cost-effectiveness of complex multimorbidity interventions. OBJECTIVE: This study examines the cost-effectiveness of a 6-week occupational therapy-led self-management support programme (OPTIMAL) for adults with multimorbidity. METHODS: Economic evaluation, from a healthcare perspective, was conducted alongside a randomized controlled trial of 149 adults with multimorbidity. Intervention was the OPTIMAL programme with a comparison of usual primary care. Incremental costs, quality-adjusted life years (QALYs) gained, and expected cost-effectiveness were estimated at 6 months and uncertainty was explored using cost-effectiveness acceptability curves. RESULTS: The intervention was associated with a mean improvement in QALYs gained of 0.031 per patient (P-value: 0.063; 95% confidence intervals [CIs]: -0.002 to 0.063) and a mean reduction in total costs of €2,548 (P-value: 0.114; 95% CIs: -5,606 to 509) per patient. At cost-effectiveness threshold values of €20,000 and €45,000 per QALY, the probability of the intervention being cost-effective was estimated to be 0.951 and 0.958, respectively. The results remained consistent across all subgroups examined. CONCLUSIONS: This study adds to the limited evidence base on the cost-effectiveness of complex interventions for multimorbidity, and highlights the potential for the OPTIMAL programme to be cost-effective. Further studies are warranted to explore the clinical and cost-effectiveness of complex interventions for the multimorbidity patient population, and for subgroups within it. TRIAL REGISTRATION: Trial number: ISRCTN67235963.

摘要

背景:多种疾病并存是一个主要的公共卫生问题。鉴于患者的个体化和多变的需求,包含个体化护理计划的复杂干预措施可能适用于多种疾病并存的患者。目前,关于复杂多种疾病干预措施的成本效益证据很少。

目的:本研究旨在评估 6 周职业治疗主导的自我管理支持计划(OPTIMAL)治疗多种疾病并存的成年人的成本效益。

方法:从医疗保健的角度进行经济评估,同时对 149 名多种疾病并存的成年人进行了一项随机对照试验。干预措施是 OPTIMAL 计划,与常规初级保健进行比较。在 6 个月时估计增量成本、获得的质量调整生命年(QALYs)和预期成本效益,并使用成本效益接受性曲线探索不确定性。

结果:干预组患者获得的 QALY 平均提高 0.031 个(P 值:0.063;95%置信区间 [CI]:-0.002 至 0.063),总费用平均降低 2548 欧元(P 值:0.114;95% CI:-5606 至 509)。在成本效益阈值为 20000 欧元和 45000 欧元/QALY 时,干预措施具有成本效益的概率估计分别为 0.951 和 0.958。在所有检查的亚组中,结果均保持一致。

结论:本研究增加了复杂干预措施治疗多种疾病并存的成本效益的有限证据基础,并强调了 OPTIMAL 计划具有成本效益的潜力。需要进一步研究来探索复杂干预措施对多种疾病并存患者人群及其亚组的临床和成本效益。

试验注册:试验编号:ISRCTN67235963。

相似文献

[1]
Cost-effectiveness of an occupational therapy-led self-management support programme for multimorbidity in primary care.

Fam Pract. 2022-9-24

[2]
Group cognitive-behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations.

Health Technol Assess. 2019-10

[3]
BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A.

Health Technol Assess. 2010-5

[4]
REDUCING POTENTIALLY INAPPROPRIATE PRESCRIBING FOR OLDER PEOPLE IN PRIMARY CARE: COST-EFFECTIVENESS OF THE OPTI-SCRIPT INTERVENTION.

Int J Technol Assess Health Care. 2017-10-11

[5]
Cost-effectiveness of a patient-centred approach to managing multimorbidity in primary care: a pragmatic cluster randomised controlled trial.

BMJ Open. 2020-1-19

[6]
Effect of the OPTIMAL programme on self-management of multimorbidity in primary care: a randomised controlled trial.

Br J Gen Pract. 2021-4

[7]
Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation.

Health Technol Assess. 2020-9

[8]
Cost-Effectiveness of Facilitated Access to a Self-Management Website, Compared to Usual Care, for Patients With Type 2 Diabetes (HeLP-Diabetes): Randomized Controlled Trial.

J Med Internet Res. 2018-6-8

[9]
Randomised controlled trial evaluating the effectiveness and cost-effectiveness of 'Families for Health', a family-based childhood obesity treatment intervention delivered in a community setting for ages 6 to 11 years.

Health Technol Assess. 2017-1

[10]

2022-12

引用本文的文献

[1]
Multimorbidity Management: A Scoping Review of Interventions and Health Outcomes.

Int J Environ Res Public Health. 2025-5-13

[2]
Primary care occupational therapist's methods of outcome evaluation: Do they align to value-based healthcare?

Br J Occup Ther. 2025-6

[3]
A global profile of occupational therapy and primary care: Results from the World Federation of Occupational Therapists survey.

Hong Kong J Occup Ther. 2025-4-3

[4]
The cost effectiveness of early assessment and intervention by a dedicated health and social care professional team for older adults in the emergency department compared to treatment-as-usual: Economic evaluation of the OPTI-MEND trial.

PLoS One. 2024

[5]
Economic evaluations of interventional opportunities for the management of mental-physical multimorbidity: a systematic review.

BMJ Open. 2023-2-28

本文引用的文献

[1]
Effect of the OPTIMAL programme on self-management of multimorbidity in primary care: a randomised controlled trial.

Br J Gen Pract. 2021-4

[2]
Cost-effectiveness of a patient-centred approach to managing multimorbidity in primary care: a pragmatic cluster randomised controlled trial.

BMJ Open. 2020-1-19

[3]
Prevalence of multimorbidity in community settings: A systematic review and meta-analysis of observational studies.

J Comorb. 2019-8-22

[4]
Evidence on multimorbidity from definition to intervention: An overview of systematic reviews.

Ageing Res Rev. 2017-5-13

[5]
Occupational Therapy and Management of Multiple Chronic Conditions in the Context of Health Care Reform.

Am J Occup Ther. 2017

[6]
Do primary care professionals agree about progress with implementation of primary care teams: results from a cross sectional study.

BMC Fam Pract. 2016-11-22

[7]
Multimorbidity and mortality in older adults: A systematic review and meta-analysis.

Arch Gerontol Geriatr. 2016

[8]
The CARE Plus study - a whole-system intervention to improve quality of life of primary care patients with multimorbidity in areas of high socioeconomic deprivation: exploratory cluster randomised controlled trial and cost-utility analysis.

BMC Med. 2016-6-22

[9]
Interventions for improving outcomes in patients with multimorbidity in primary care and community settings.

Cochrane Database Syst Rev. 2016-3-14

[10]
Multimorbidity and functional decline in community-dwelling adults: a systematic review.

Health Qual Life Outcomes. 2015-10-15

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索